Fora Capital, LLC Abb Vie Inc. Transaction History

Fora Capital, LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	BUY	$137.6 - $154.97 $4.16 Million - $4.68 Million	30,229 New	30,229 $4.68 Million
Q2 2023 Aug 11, 2023	BUY	$132.51 - $164.9 $7.51 Million - $9.34 Million	56,652 New	56,652 $7.63 Million
Q4 2022 Feb 08, 2023	BUY	$138.31 - $165.87 $2.91 Million - $3.49 Million	21,045 New	21,045 $3.4 Million
Q2 2022 Aug 11, 2022	SELL	$137.62 - $174.96 $2.51 Million - $3.19 Million	-18,216 Reduced 82.54%	3,852 $590,000
Q1 2022 May 12, 2022	BUY	$131.98 - $163.75 $2.39 Million - $2.96 Million	18,100 Added 456.15%	22,068 $3.61 Million
Q4 2021 Feb 11, 2022	BUY	$107.43 - $135.93 $426,282 - $539,370	3,968 New	3,968 $537,000
Q3 2021 Nov 15, 2021	SELL	$106.4 - $120.78 $2.28 Million - $2.58 Million	-21,394 Closed	0 $0
Q2 2021 Aug 16, 2021	BUY	$105.21 - $117.21 $2.25 Million - $2.51 Million	21,394 New	21,394 $2.41 Billion
Q3 2020 Nov 13, 2020	SELL	$85.91 - $100.83 $2.35 Million - $2.75 Million	-27,314 Closed	0 $0
Q2 2020 Aug 14, 2020	BUY	$73.37 - $98.18 $1.57 Million - $2.1 Million	21,379 Added 360.22%	27,314 $2.68 Billion
Q1 2020 May 15, 2020	BUY	$64.5 - $97.79 $382,807 - $580,383	5,935 New	5,935 $452,000

3,853

1.25B

16.8M

12.2M

Ticker ABBV
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,768,099,968
Market Cap $318B
Description
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...

Get notified when there are updates to the investment portfolio of Fora Capital, LLC, based on Form 13F filings with the SEC.

Stay updated on Fora Capital, LLC with notifications on news.